Ghana has begun distributing Coartem Baby, the first antimalarial medication specifically formulated for infants under six months old [1].

This rollout addresses a critical gap in pediatric care because infants in this age group previously had no malaria treatment designed for them [1], [2]. With malaria remaining a leading cause of death among young children in Africa, the availability of a tailored dosage is expected to reduce mortality rates among newborns and young infants [1], [2].

The initiative is a partnership between Ghana's health authorities, the World Health Organization (WHO), and Novartis, the developer of the drug [1], [2], [3]. The medication combines artemether and lumefantrine [2]. The rollout followed WHO pre-qualification of the drug in early 2024, timed ahead of World Malaria Day on April 25, 2024 [2], [1].

Health clinics across Ghana are now providing the treatment to eligible patients [1], [4]. The need for such a targeted intervention is underscored by the scale of the disease in the region. Malaria kills hundreds of thousands of people across Africa each year [1].

Children are disproportionately affected by the disease. Data shows that children under five account for more than two-thirds of all malaria deaths [2]. By providing a safe, formulated dose for those under six months, health authorities aim to protect the most vulnerable window of early childhood development.

The drug's approval and subsequent distribution in Ghana mark a significant shift in how the region manages neonatal and infant health. By utilizing the WHO pre-qualification process, the medication met international standards for safety and efficacy before reaching Ghanaian clinics [2], [3].

“Infants under six months previously had no malaria treatment designed for them.”

The introduction of Coartem Baby represents a shift toward precision medicine in public health. By closing the treatment gap for infants under six months, health authorities can potentially lower the overall child mortality rate in sub-Saharan Africa, where the lack of age-appropriate medication previously left the youngest patients without a standardized pharmaceutical defense against malaria.